Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

Clinical Colorectal Cancer

Volumn 16, Issue 3, 2017, Pages e191-e198

  Pietrantonio, Filippo ^a   Di Bartolomeo, Maria ^a   Cotsoglou, Christian ^a   Mennitto, Alessia ^a   Berenato, Rosa ^a   Morano, Federica ^a   Coppa, Jorgelina ^a   Perrone, Federica ^a   Iacovelli, Roberto ^b   Milione, Massimo ^a   Alessi, Alessandra ^a   Vaiani, Marta ^a   Bossi, Ilaria ^a   Ricchini, Francesca ^a   Scotti, Mauro ^a   Caporale, Marta ^c   Bajetta, Emilio ^d   de Braud, Filippo ^a,e   Mazzaferro, Vincenzo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Medical Oncology   (Italy)

^d Policlinico di Monza   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Liver metastases; Liver resection; Triplet chemotherapy

Indexed keywords

CAPECITABINE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DIARRHEA; DRUG SAFETY; EDEMA; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; INFECTION; LIVER RESECTION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PHLEBITIS; POSTOPERATIVE COMPLICATION; PREOPERATIVE CHEMOTHERAPY; RADIOFREQUENCY ABLATION; RASH; RECURRENCE RISK; THROMBOSIS; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SECONDARY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CAPECITABINE; CETUXIMAB; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS;

EID: 85006055062     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.09.007     Document Type: Article

References (36)

1. Abdalla, E.K., Vauthey, J.N., Ellis, L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 (2004), 818–827.
2. Bittoni, A., Scartozzi, M., Giampieri, R., et al. The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language?. Crit Rev Oncol Hematol 85 (2013), 332–341.
3. Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008), 1007–1016.
4. Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14 (2013), 1208–1215.
5. Van Cutsem, E., Cervantes, A., Adam, R., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27 (2016), 1386–1422.
6. Adam, R., Delvart, V., Pascal, G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 (2004), 644–657.
7. Adam, R., Wicherts, D.A., de Haas, R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 27 (2009), 1829–1835.
8. Folprecht, G., Grothey, A., Alberts, S., Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005), 1311–1319.
9. de Jong, M.C., Pulitano, C., Ribero, D., et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250 (2009), 440–448.
10. Masi, G., Loupakis, F., Pollina, L., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249 (2009), 420–425.
11. Gruenberger, T., Bridgewater, J., Chau, I., et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26 (2015), 702–708.
12. Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
13. Ye, L.C., Liu, T.S., Ren, L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31 (2013), 1931–1938.
14. Bajetta, E., Celio, L., Ferrario, E., et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 18 (2007), 1810–1816.
15. Di Bartolomeo, M., Pietrantonio, F., Perrone, F., et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 9 (2014), 155–162.
16. Rubbia-Brandt, L., Giostra, E., Brezault, C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18 (2007), 299–304.
17. Petrelli, F., Pietrantonio, F., Cremolini, C., et al. Early tumour shrinkage as a prognostic factor and surrogate end point in colorectal cancer: a systematic review and pooled-analysis. Eur J Cancer 51 (2015), 800–807.
18. Cremolini, C., Loupakis, F., Antoniotti, C., et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26 (2015), 1188–1194.
19. Douillard, J.Y., Oliner, K.S., Siena, S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
20. Petrelli, F., Barni, S., Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis 27 (2012), 997–1004.
21. Van Cutsem, E., Lenz, H.J., Köhne, C.H., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33 (2015), 692–700.
22. Van Cutsem, E., Köhne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
23. Fornaro, L., Lonardi, S., Masi, G., et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 24 (2013), 2062–2067.
24. Primrose, J., Falk, S., Finch-Jones, M., et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15 (2014), 601–611.
25. Nordlinger, B., Poston, G.J., Goldberg, R.M., Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?. J Clin Oncol 33 (2015), 241–243.
26. Antoniotti, C., Cremolini, C., Loupakis, F., et al. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO. (abstract 3543) J Clin Oncol, 34(suppl), 2016.
27. Klinger, M., Tamandl, D., Eipeldauer, S., et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17 (2010), 2059–2065.
28. Pietrantonio, F., Orlandi, A., Inno, A., et al. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: pitfalls and helpful tricks in a review for clinicians. Crit Rev Oncol Hematol 95 (2015), 272–281.
29. Pietrantonio, F., Mazzaferro, V., Miceli, R., et al. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol, 32, 2015, 638.
30. Adam, R., Wicherts, D.A., de Haas, R.J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?. J Clin Oncol 26 (2008), 1635–1641.
31. Di Bartolomeo, M., Ciarlo, A., Bertolini, A., et al. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. Eur J Cancer 51 (2015), 473–481.
32. Vale, C.L., Tierney, J.F., Fisher, D., et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 38 (2012), 618–625.
33. Falvella, F.S., Cheli, S., Martinetti, A., et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol 80 (2015), 581–588.
34. Iacovelli, R., Pietrantonio, F., Palazzo, A., et al. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol 8 (2014), 1228–1237.
35. Schirripa, M., Bergamo, F., Cremolini, C., et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 112 (2015), 1921–1928.
36. Pietrantonio, F., Petrelli, F., Coinu, A., et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer 51 (2015), 587–594.